KDR and vascular neoplasm: To investigate the role of angiogenesis in the response of tumor cells to the EGFR-tyrosine kinase inhibitor (TKI) treatment used in clinical trials, it is necessary to integrate the drug treatment effects of an EGFR inhibitor targeting tumor cells and a VEGFR inhibitor targeting endothelial cells into a multiscale model of vascular tumor.